These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27333031)

  • 1. Donor-specific antibodies require preactivated immune system to harm renal transplant.
    Süsal C; Döhler B; Ruhenstroth A; Morath C; Slavcev A; Fehr T; Wagner E; Krüger B; Rees M; Balen S; Živčić-Ćosić S; Norman DJ; Kuypers D; Emonds MP; Pisarski P; Bösmüller C; Weimer R; Mytilineos J; Scherer S; Tran TH; Gombos P; Schemmer P; Zeier M; Opelz G;
    EBioMedicine; 2016 Jul; 9():366-371. PubMed ID: 27333031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The possible critical role of T-cell help in DSA-mediated graft loss.
    Süsal C; Slavcev A; Pham L; Zeier M; Morath C
    Transpl Int; 2018 Jun; 31(6):577-584. PubMed ID: 29405445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
    Vaidya S; Partlow D; Barnes T; Gugliuzza K
    Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
    Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
    Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.
    Süsal C; Pelzl S; Opelz G
    Transplantation; 2003 Oct; 76(8):1231-2. PubMed ID: 14578759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30.
    Süsal C; Pelzl S; Döhler B; Opelz G
    J Am Soc Nephrol; 2002 Jun; 13(6):1650-6. PubMed ID: 12039995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
    Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
    Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies.
    Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Mohammadiazar S; Solgi G
    Hum Immunol; 2014 Jan; 75(1):47-58. PubMed ID: 24055694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplant human leukocyte antigen antibodies detected by single-antigen bead assay are a risk factor for long-term kidney graft loss even in the absence of donor-specific antibodies.
    Richter R; Süsal C; Köhler S; Qidan S; Schödel A; Holschuh L; Brzoska M; Asbe-Vollkopf A; Büttner S; Betz C; Herrmann E; Gauer S; Seifried E; Geiger H; Seidl C; Hauser IA
    Transpl Int; 2016 Sep; 29(9):988-98. PubMed ID: 27103066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of immune status of kidney transplant recipients by combined HLA-G5 and sCD30].
    JIN ZK; TIAN PX; XUE WJ; DING XM; PAN XM; DING CG; JIA LN; GE GQ; HAO JJ
    Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(36):2528-31. PubMed ID: 21092456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft.
    Pavlova Y; Viklicky O; Slatinska J; Bürgelova M; Süsal C; Skibova J; Honsová E; Striz I; Kolesar L; Slavcev A
    Transpl Immunol; 2011 Jul; 25(1):72-6. PubMed ID: 21376809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
    Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients.
    Fichtner A; Süsal C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Opelz G; Tönshoff B
    Pediatr Nephrol; 2016 Jul; 31(7):1157-66. PubMed ID: 26928311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.